Quadrant Capital Group LLC Apellis Pharmaceuticals, Inc. Transaction History
Quadrant Capital Group LLC
- $3 Billion
- Q3 2025
A detailed history of Quadrant Capital Group LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 169 shares of APLS stock, worth $3,435. This represents 0.0% of its overall portfolio holdings.
Number of Shares
169Holding current value
$3,435% of portfolio
0.0%Shares
11 transactions
Others Institutions Holding APLS
# of Institutions
319Shares Held
123MCall Options Held
3.57MPut Options Held
778K-
Avoro Capital Advisors LLC New York, NY12.2MShares$248 Million3.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.99MShares$203 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.64MShares$196 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.29MShares$189 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8MShares$163 Million5.71% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.23B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...